Sensorion SA (EPA:ALSEN)

Market Cap	217.73M +126.4%
Revenue (ttm)	5.81M -12.6%
Net Income	-29.43M
EPS	-0.10
Shares Out	514.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,859,091
Open	0.4160
Previous Close	0.4230
Day's Range	0.3900 - 0.4160
52-Week Range	0.2730 - 0.8080
Beta	0.36
Analysts	Strong Buy
Price Target	1.30 (+229.95%)
Earnings Date	Mar 30, 2026

About Sensorion

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 63
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALSEN

Financial Performance

In 2025, Sensorion's revenue was 5.81 million, a decrease of -12.61% compared to the previous year's 6.65 million. Losses were -29.43 million, 13.3% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ALSEN stock is "Strong Buy." The 12-month stock price target is €1.30, which is an increase of 229.95% from the latest price.

Price Target

€1.30

(229.95% upside)

Analyst Consensus: Strong Buy